



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

zel

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/622,302	07/18/2003	Karen Stec	ALS-2	7280

7590
Jeffrey M. Hoster
13 Woodland Drive
Lemont, IL 60439

08/09/2007

EXAMINER

CLAYTOR, DEIRDRE RENEE

ART UNIT PAPER NUMBER

1617

MAIL DATE DELIVERY MODE

08/09/2007

PAPER

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

Office Action Summary

Application No.

10/622,302

Applicant(s)

STEC ET AL.

Examiner

Renee Claytor

Art Unit

1617

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

- 1) ☒ Responsive to communication(s) filed on 31 May 2007.
- 2a) ☐ This action is **FINAL**. 2b) ☒ This action is non-final.
- 3) ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims

- 4) ☒ Claim(s) 34-43 is/are pending in the application.
- 4a) Of the above claim(s) 43 is/are withdrawn from consideration.
- 5) ☐ Claim(s) _____ is/are allowed.
- 6) ☒ Claim(s) 34-42 is/are rejected.
- 7) ☐ Claim(s) _____ is/are objected to.
- 8) ☐ Claim(s) _____ are subject to restriction and/or election requirement.

Application Papers

- 9) ☐ The specification is objected to by the Examiner.
- 10) ☐ The drawing(s) filed on _____ is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
- 11) ☐ The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

Priority under 35 U.S.C. § 119

- 12) ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
- a) ☐ All b) ☐ Some * c) ☐ None of:
- ☐ Certified copies of the priority documents have been received.
 - ☐ Certified copies of the priority documents have been received in Application No. _____.
 - ☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).
- * See the attached detailed Office action for a list of the certified copies not received.

Attachment(s)

- ☐ Notice of References Cited (PTO-892)
- ☐ Notice of Draftsperson's Patent Drawing Review (PTO-948)
- ☐ Information Disclosure Statement(s) (PTO/SB/08)
Paper No(s)/Mail Date _____
- ☐ Interview Summary (PTO-413)
Paper No(s)/Mail Date _____
- ☐ Notice of Informal Patent Application
- ☐ Other: _____

DETAILED ACTION

Response to Arguments

Applicant argues that because Claims 1-8 and 15-23 were stated as being free of the art in the previous Office Action, the claims directed to a method for treating dysfunction, damage and/or injuries to organs, tissues and/or cells in human subjects with 2,3-diacetoxybenzoic acid should be patentable. This argument is not persuasive because the statement was put forth as the claims were examined as they read on the elected species of ischemia/reperfusion and not to all dysfunctions, damage and/or injuries to organs, tissues, and/or cells. The cancellation of claims 1-33 and addition of new claims 34-43 necessitates the following new grounds of rejection.

Newly submitted claim 43 is directed to an invention that is independent or distinct from the invention originally claimed for the following reasons: the method for treating lung injury was not initially examined because this limitation was not part of the elected species of ischemia/reperfusion injury.

Since applicant has received an action on the merits for the originally presented invention, this invention has been constructively elected by original presentation for prosecution on the merits. Accordingly, claim 43 is withdrawn from consideration as being directed to a non-elected invention. See 37 CFR 1.142(b) and MPEP § 821.03.

Claim Rejections – 35 U.S.C. § 112

The following is a quotation of the first paragraph of 35 U.S.C. 112:

Art Unit: 1617

The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same and shall set forth the best mode contemplated by the inventor of carrying out his invention.

Claims 34-42 are rejected under 35 U.S.C. 112, first paragraph, because the specification does not reasonably provide enablement for treating the elected species of ischemia/reperfusion. The claim(s) contains subject matter which was not described in the specification in such a way as to enable one skilled in the art to which it pertains, or with which it is most nearly connected, to make and/or use the invention.

The how to make requirement of the enablement statute, when applied to process claims, refers to operability and how to make the claimed process work. "The factors to be considered [in making an enablement rejection] have been summarized as the quantity of experimentation necessary, the amount of direction or guidance presented, the presence or absence of working examples, the nature of the invention, the state of the prior art, the relative skill of those in that art, the predictability or unpredictability of the art and the breadth of the claims", *In re Rainer*, 146 USPQ 218 (1965); *In re Colianni*, 195 USPQ 150, *Ex parte Formal*, 230 USPQ 546.

(1) The nature of the invention and breadth of the claims: The rejected claims 34-42 are drawn to a method for treating dysfunction, damage and/or injuries to organs, tissues, and/or cells, specifically the elected species ischemia/reperfusion; comprising administration of 2,3-diacetoxybenzoic acid.

(2) The amount of guidance or direction presented and the presence or absence of working examples: In the instant case, no working examples are presented in the specification as filed showing how to treat ischemia/reperfusion with

2,3-diacetoxybenzoic acid. Note that lack of a working example is a critical factor to be considered, especially in a case involving an unpredictable and undeveloped art. See MPEP § 2164. The specification on pages 10-11 details studies performed in guinea pig models of lung injury and sepsis in which 2,3-diacetoxybenzoic acid treatment was shown to improve lung injury and sepsis proving that 2,3-diacetoxybenzoic acid improves lung injury and sepsis; however, the specification does not provide examples for treating ischemia/reperfusion with 2,3-diacetoxybenzoic acid.

(3) The state of the prior art: The "amount of guidance or direction" refers to that information in the application, as originally filed, that teaches exactly how to make or use the invention. The more that is known in the prior art about the nature of the invention, how to make, and how to use the invention, and the more predictable the art is, the less information needs to be explicitly stated in the specification. In contrast, if little is known in the prior art about the nature of the invention and the art is unpredictable, the specification would need more details as to how to make and use invention in order to be enabling. >See, e.g., *Chiron Corp. v. Genentech Inc.*, 363 F.3d 1247, 1254; 70 USPQ2d 1321, 1326 (Fed. Cir. 2004).

The state of the art regarding the treatment of ischemia/reperfusion is provided by Cuzzocrea et al. in which different treatment options are presented for ischemia/reperfusion injury, none of which include 2,3-diacetoxybenzoic acid (see pgs. 152-153; *Pharmacol Rev* 53: 135-159, 2001). Therefore the use of 2,3-diacetoxybenzoic acid is not an art recognized treatment option for ischemia/reperfusion injury at the time of the invention.

Art Unit: 1617

(4) The quantitation of experimentation necessary: Claims 34-42 read on the treatment of dysfunctions, damage and/or injuries to organs, tissues and/or cells, and more specifically the elected species ischemia/reperfusion, comprising administration of 2,3-diacetoxybenzoic acid. As discussed above, the specification fails to provide sufficient support for treating ischemia/reperfusion comprising administration of 2,3-diacetoxybenzoic acid. Applicant fails to provide information sufficient to practice the claimed invention, absent undue experimentation. Genetech, 108 F.3d at 1366 states that "a patent is not a hunting license. It is not a reward for search, but compensation for its successful conclusion" and "patent protection is granted in return for an enabling disclosure of an invention, not for vague intimations of general ideas that may or may not be workable".

The following is a quotation of the second paragraph of 35 U.S.C. 112:

The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention.

Claim s 40-42 recites the limitation "...for the prevention and treatment of blood clots....". There is insufficient antecedent basis for this limitation in the claim. Claim 34 is drawn to a method of treatment and the term "prevention" in claim 40 broadens the scope of the independent claim.

Conclusion

No claims are allowed.

Art Unit: 1617


Contact Information

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Renee Claytor whose telephone number is 571-272-8394. The examiner can normally be reached on M-F 8:00-4:30.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Sreeni Padmanabhan can be reached on 571-272-0629. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

Renee Claytor


SREENI PADMANABHAN
SUPERVISORY PATENT EXAMINER